11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Metabolic Reprogramming of Terminally Exhausted CD8 + T cells by IL-10 Enhances Anti-Tumor Immunity

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          T cell exhaustion presents one of the major hurdles to cancer immunotherapy. Among exhausted CD8 + tumor-infiltrating lymphocytes (TILs), the terminally exhausted subset contributes directly to tumor cell killing owing to its cytotoxic effector function. However, this subset does not respond to immune checkpoint blockades and is difficult to be reinvigorated with restored proliferative capacity. Here, we show that a half-life–extended interleukin (IL)-10/Fc fusion protein directly and potently enhanced expansion and effector function of terminally exhausted CD8 + TILs by promoting oxidative phosphorylation (OXPHOS), a process independent of the progenitor exhausted T cells. IL-10/Fc was a safe and highly efficient metabolic intervention that synergized with adoptive T cell transfer immunotherapy, leading to eradication of established solid tumors and durable cures in a majority of treated mice. These findings show that metabolic reprogramming by upregulating mitochondrial pyruvate carrier-dependent OXPHOS can revitalize terminally exhausted T cells and enhance the response to cancer immunotherapy.

          Related collections

          Most cited references58

          • Record: found
          • Abstract: found
          • Article: not found

          Elements of cancer immunity and the cancer–immune set point

          Immunotherapy is proving to be an effective therapeutic approach in a variety of cancers. But despite the clinical success of antibodies against the immune regulators CTLA4 and PD-L1/PD-1, only a subset of people exhibit durable responses, suggesting that a broader view of cancer immunity is
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

            Cancer immunotherapy can induce long lasting responses in patients with metastatic cancers of a wide range of histologies. Broadening the clinical applicability of these treatments requires an improved understanding of the mechanisms limiting cancer immunotherapy. The interactions between the immune system and cancer cells are continuous, dynamic, and evolving from the initial establishment of a cancer cell to the development of metastatic disease, which is dependent on immune evasion. As the molecular mechanisms of resistance to immunotherapy are elucidated, actionable strategies to prevent or treat them may be derived to improve clinical outcomes for patients.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9

              CRISPR-Cas9-based genetic screens are a powerful new tool in biology. By simply altering the sequence of the single-guide RNA (sgRNA), Cas9 can be reprogrammed to target different sites in the genome with relative ease, but the on-target activity and off-target effects of individual sgRNAs can vary widely. Here, we use recently-devised sgRNA design rules to create human and mouse genome-wide libraries, perform positive and negative selection screens and observe that the use of these rules produced improved results. Additionally, we profile the off-target activity of thousands of sgRNAs and develop a metric to predict off-target sites. We incorporate these findings from large-scale, empirical data to improve our computational design rules and create optimized sgRNA libraries that maximize on-target activity and minimize off-target effects to enable more effective and efficient genetic screens and genome engineering.
                Bookmark

                Author and article information

                Journal
                100941354
                Nat Immunol
                Nat Immunol
                Nature immunology
                1529-2908
                1529-2916
                23 April 2021
                01 June 2021
                24 May 2021
                24 November 2021
                : 22
                : 6
                : 746-756
                Affiliations
                [1 ]Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland
                [2 ]Institute of Materials Science & Engineering, EPFL, 1015 Lausanne, Switzerland
                [3 ]Department of Oncology, University of Lausanne, 1066 Epalinges, Switzerland
                [4 ]Ludwig Institute for Cancer Research, University of Lausanne, 1066 Epalinges, Switzerland
                [5 ]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, 610041 Chengdu, China
                [6 ]Center for Genomics and Systems Biology, New York University Abu Dhabi, 129188 Abu Dhabi, United Arab Emirates
                [7 ]Siriraj Center of Research Excellence for Systems Pharmacology, Department of Pharmacology, Faculty of Medicine, Siriraj Hospital, Mahidol University, 10700 Bangkok, Thailand
                [8 ]Department of Respiratory and Critical Care Medicine, West China Medical School/West China Hospital, Sichuan University, 610041 Chengdu, China
                [9 ]Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, Department of Oncology of the First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, 230026 Hefei, China
                Author notes
                Article
                EMS123191
                10.1038/s41590-021-00940-2
                7610876
                34031618
                ac57a29a-4a98-49fd-bb7c-0952b16362f2

                Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Categories
                Article

                Immunology
                Immunology

                Comments

                Comment on this article